Immunization against a Saccharide Epitope Accelerates Clearance of Experimental Gonococcal Infection

PLoS Pathogens

Volumn 9, Issue 8, 2013, Pages

  Gulati, Sunita ^a   Zheng, Bo ^a   Reed, George W ^a   Su, Xiaohong ^a,b   Cox, Andrew D ^c   St Michael, Frank ^c   Stupak, Jacek ^c   Lewis, Lisa A ^a   Ram, Sanjay ^a   Rice, Peter A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; GLYCOSYLTRANSFERASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY 2C7; MULTI ANTIGENIC PEPTIDE 1; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDE;

ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTIONATION; GONORRHEA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; SERUM BACTERICIDAL ANTIBODY ASSAY; ADULT; ANIMAL; BAGG ALBINO MOUSE; CLINICAL TRIAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; MALE; MICROBIOLOGY; PATHOLOGY; TH1 CELL;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; GONORRHEA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; NEISSERIA GONORRHOEAE; PEPTIDES; POLYSACCHARIDES, BACTERIAL; TH1 CELLS;

EID: 84883326706     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003559     Document Type: Article

References (55)

1. WHO (2012) Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance of Neisseria gonorrhoeae. Geneva: World Health Organization ISBN 978 92 4 150350 1.
2. Hook EW, Handsfield HH (1999) Gonococcal infection in the adult. In: Holmes KKMP, Sparling PF, Lemon SM, Stamm WE, Piot P, Wasserheit JN, editors. Sexually transmitted diseases New York: McGraw-Hill. 451-466.
3. Weir SS, Feldblum PJ, Roddy RE, Zekeng L, (1994) Gonorrhea as a risk factor for HIV acquisition. AIDS 8: 1605-1608.
4. Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, et al. (2012) In Vitro Activity of Ertapenem versus Ceftriaxone against Neisseria gonorrhoeae Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea? Antimicrobial agents and chemotherapy 56: 3603-3609.
5. Russell MW, Hedges SR, Wu HY, Hook EW, (1999) Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases-a review. American journal of reproductive immunology 42: 58-63.
6. Rice PA, Vayo H, Tam M, Blake MS, (1986) Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. Journal of experimental medicine 164: 1735-1748.
7. Rice PA, (1989) Molecular basis for serum resistance in Neisseria gonorrhoeae. Clinical microbiology review 2S: S112-S117.
8. Densen P, Gulati S, Rice PA, (1987) Specificity of antibodies against Neisseria gonorrhoeae that stimulate neutrophil chemotaxis. Role of antibodies directed against lipooligosaccharides. The Journal of clinical investigation 80: 78-87.
9. Gulati S, McQuillen DP, Mandrell RE, Jani DB, Rice PA, (1996) Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope, 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolopids. The Journal of infectious diseases 174: 1223-1237.
10. Schmidt KA, Schneider H, Lindstrom JA, Boslego JW, Warren RA, et al. (2001) Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers. Sexually transmitted diseases 28: 555-564.
11. Ngampasutadol J, Rice PA, Walsh MT, Gulati S, (2006) Characterization of a peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria gonorrhoeae and resultant immune responses and function. Vaccine 24: 157-170.
12. Yamasaki R, Koshino H, Kurono S, Nishinaka Y, McQuillen DP, et al. (1999) Structural and immunochemical characterization of a Neisseria gonorrhoeae epitope defined by a monoclonal antibody 2C7; the antibody recognizes a conserved epitope on specific lipo-oligosaccharides in spite of the presence of human carbohydrate epitopes. The Journal of biological chemistry 51: 36550-36558.
13. Perlmutter RM, Hansburg D, Briles DE, Nicolotti RA, Davie JM, (1978) Subclass restriction of murine anti-carbohydrate antibodies. Journal of immunology 121: 566-572.
14. Goletz S, Christensen PA, Kristensen P, Blohm D, Tomlinson I, et al. (2002) Selection of large diversities of antiidiotypic antibody fragments by phage display. Journal of molecular biology 315: 1087-1097.
15. Lesinski GB, Westerink MA, (2001) Novel vaccine strategies to T-independent antigens. Journal of microbiological methods 47: 135-149.
16. Paoletti LC, Kasper DL, (2003) Glycoconjugate vaccines to prevent group B streptococcal infections. Expert opinion on biological therapy 3: 975-984.
17. Buchwald UK, Lees A, Steinitz M, Pirofski LA, (2005) A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infection and immunity 73: 325-333.
18. Apicella MA, Bennett KM, Hermerath CA, Roberts DE, (1981) Monoclonal antibody analysis of lipopolysaccharide from Neisseria gonorrhoeae and Neisseria meningitidis. Infection and immunity 34: 751-756.
19. Schneider H, Hale TL, Zollinger WD, Seid R Jr, Hammack CA, et al. (1984) Heterogeneity of molecular size and antigenic expression within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis. Infection and immunity 45: 544-549.
20. Verheul AF, Boons GJ, Van der Marel GA, Van Boom JH, Jennings HJ, et al. (1991) Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infection and immunity 59: 3566-3573.
21. Wakarchuk WW, Gilbert M, Martin A, Wu Y, Brisson JR, et al. (1998) Structure of an alpha-2,6-sialylated lipooligosaccharide from Neisseria meningitidis immunotype L1. European journal of biochemistry 254: 626-633.
22. Scott MG, Briles DE, H. NM (1990) Selective IgG subclass expression: biologic, clinical and functional aspects, p. 161-183. In F. Shakib (ed.), The human IgG subclasses: molecular analysis of structure and function. Pergamon Press, Oxford.
23. Criss AK, Seifert HS, (2012) A bacterial siren song: intimate interactions between Neisseria and neutrophils. Nature reviews Microbiology 10: 178-190.
24. Ngampasutadol J, Tran C, Gulati S, Blom AM, Jerse AE, et al. (2008) Species-specificity of Neisseria gonorrhoeae infection: Do human complement regulators contribute? Vaccine 26S: 162-166.
25. Zhu W, Chen CJ, Thomas CE, Anderson JE, Jerse AE, et al. (2011) Vaccines for gonorrhea: can we rise to the challenge? Frontiers in microbiology 2: 124.
26. Kasper DL, Rice PA, McCormack WM, (1977) Bactericidal antibody in genital infection due to Neisseria gonorrhoeae. The Journal of infectious diseases 135: 243-251.
27. Plummer FA, Ndinya-Achola JO, Bosire M, Brunham RC, Chubb H, et al. (1993) Antibody to Rmp (outer membrane protein 3) Increases susceptability to gonococcal infection. The Journal of clinical investigation 91: 339-443.
28. Boulton IC, Gray-Owen SD, (2002) Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nature immunology 3: 229-236.
29. Feinen B, Jerse AE, Gaffen SL, Russell MW, (2010) Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal immunology 3: 312-321.
30. Johnson MB, Criss AK, (2011) Resistance of Neisseria gonorrhoeae to neutrophils. Frontiers in microbiology 2: 77.
31. Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, et al. (2011) Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Frontiers in microbiology 2: 107.
32. Ngampasutadol J, Ram S, Blom AM, Jarva H, Jerse AE, et al. (2005) Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A 102: 17142-17147.
33. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, et al. (2008) Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol 180: 3426-3435.
34. Plummer FA, Simonsen J, Chubb H, Staney L, Kimata J, et al. (1989) Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. The Journal of clinical investigation 83: 1472-1476.
35. Hobbs MM, Alcorn TM, Davis RH, Fischer W, Thomas JC, et al. (1999) Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community. The Journal of infectious diseases 179: 371-381.
36. Barritt DS, Schwalbe RS, Klapper DG, Cannon JG, (1987) Antigenic and structural differences among six proteins II expressed by a single strain of Neisseria gonorrhoeae. Infection and immunity 55: 2026-2031.
37. Plummer FA, Chubb H, Simonsen JN, Bosire M, Slaney L, et al. (1994) Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis. The Journal of clinical investigation 93: 1748-1755.
38. Rice PA, McQuillen DP, Gulati S, Jani DB, Wetzler LM, et al. (1994) Serum resistance of Neisseria gonorrhoeae. Does it thwart the inflammatory response and facilitate the transmission of infection? Annals of the New York Academy of Sciences 730: 7-14.
39. Greenberg L, (1975) Field trials of a gonococcal vaccine. The Journal of reproductive medicine 14: 34-36.
40. Tramont EC, Boslego J, Chung R, McChesney DC, Ciak J, et al. (1985) Parenteral gonococcal pilus vaccine. In: G.K.Schoolnik, Brooks GF, Falkow S, Frasch CE, Knapp JS, et al., editors. The pathogenic neisseriae. Washington, D.C.: American Society for Microbiology. pp. 316-322.
41. Boslego JW, Tramont EC, Chung RC, McChesney DG, Ciak J, et al. (1991) Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9: 154-162.
42. Rice PA, Gulati S, McQuillen DP, Ram S (1996) Is there protective immunity to gonococcal disease? In: W.D.Zollinger, C.E.Frash, and C.D.Deal eds. the Tenth International Pathogenic Neisseria Conference. Baltimore, p 3. http://neisseria.org/ipnc/1996/Neis1996-chap1.pdf.
43. Wheeler AW, Marshall JS, Ulrich JT, (2001) A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. International archives of allergy and immunology 126: 135-139.
44. Price RJ, Boettcher B, (1979) The presence of complement in human cervical mucus and its possible relevance to infertility in women with complement-dependent sperm-immobilizing antibodies. Fertility and sterility 32: 61-66.
45. Hess C, Schifferli JA, (2003) Immune adherence revisited: novel players in an old game. News in physiological sciences: an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society 18: 104-108.
46. Karsten CM, Kohl J, (2012) The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217: 1067-1079.
47. Johnson MB, Criss AK, (2013) Neisseria gonorrhoeae Phagosomes Delay Fusion with Primary Granules to Enhance Bacterial Survival Inside Human Neutrophils. Cellular microbiology 15 (8) (): 1323-40.
48. Griffiss JM, O'Brien JP, Yamasaki R, Williams GD, Rice PA, et al. (1987) Physical heterogeneity of Neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infection and immunity 55: 1792-1800.
49. Cohen MS, Cannon JG, Jerse AE, Charniga LM, Isbey SF, et al. (1994) Human experimentation with Neisseria gonorrhoeae: Rationale, Methods, and Implications for the biology of infection and vaccine development. The Journal of infectious diseases 169: 532-537.
50. Gulati S, Cox A, Lewis LA, Michael FS, Li J, et al. (2005) Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci. Infection and immunity 73: 7390-7397.
51. Seifert HS, (1997) Insertionally inactivated and inducible recA alleles for use in Neisseria. Gene 188: 215-220.
52. Lewis LA, Gipson M, Hartman K, Ownbey T, Vaughn J, et al. (1999) Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Molecular microbiology 32: 977-989.
53. Jerse AE, (1999) Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infection and immunity 67: 5699-5708.
54. Song W, Condron S, Mocca BT, Veit SJ, Hill D, et al. (2008) Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-treated mice. Vaccine 26: 5741-5751.
55. McQuillen DP, Gulati S, Rice PA (1994) Complement-mediated bacterial killing assays. In: Clark VL, Bavoil PK, editors. Methods in enzymology. San Diego, CA: Academic Press. pp. 137-147.